Cancer clinical trials in Baltimore

Add ZEN003694 to enzalutamide for resistant prostate cancer

This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.

Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer

This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.

Zongertinib for advanced cancers with HER2 changes

This trial tests an experimental drug (zongertinib) for people with advanced solid tumors that have certain changes in the HER2 gene. It's for those who have already tried at least one standard treatment and need more options.

Safety follow-up for hormone-positive, HER2-negative breast cancer

This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.

Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer

This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.

Zanidatamab plus chemo before surgery for HER2+ breast cancer

This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.

Study of heart-risk management for metastatic HER2 breast cancer

This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.

Nerve stimulation for men with overactive bladder

This study tests a nerve stimulation device placed near the tailbone to help men with overactive bladder symptoms. If you have bothersome urinary urgency or frequency, this treatment may offer relief without drugs.

Testing a new drug combo for advanced lung cancer

This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.

Study of GDC-4198 alone or with giredestrant for advanced breast cancer

This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.

Study drug for repeat bladder tumor surgery patients

This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.

New hormone therapy for advanced breast cancer after prior treatment

This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.

Surgery-like brain radiation vs avoiding the memory center

This trial compares two ways of giving radiation to the brain for people with 5 or more brain metastases: focused stereotactic radiosurgery, or a whole-brain approach that tries to spare the memory area (with memantine). It aims to see which method better protects thinking and memory while still treating the tumors.

Study of a new drug for platinum-resistant ovarian cancer

This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.

Gene therapy vs. observation for intermediate risk bladder cancer

This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.

New drug combo for advanced lung cancer with high PD-L1

This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.

Vaccine for HER2-positive breast cancer after standard treatment

This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.

Blood test study for early cancer detection

This study is testing a new blood test to help doctors find cancer earlier. If you are 45 or older and have symptoms that might be cancer, or were recently diagnosed with cancer, you may be able to join.

Study of NXP900 plus osimertinib for EGFR lung cancer

This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.

Preventing mouth sores during breast or lung cancer treatment

This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.

Immunotherapy after surgery for lung cancer with no remaining cancer

This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.

Tested targeted drug for HER2-positive breast cancer with PIK3CA changes

This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

New drug combo for HER2-positive stomach cancer

This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.